interaction records 54 assistance programs 55 0 personal data stored

Generic competition · all medicines · read 12 November 2026

Is there a generic of Meloxicam; Rizatriptan Benzoate, and who makes it?

Meloxicam; Rizatriptan Benzoate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Meloxicam; Rizatriptan Benzoate1 dosage-form group in the Orange Book
0generic makers listed
  1. Meloxicam; Rizatriptan Benzoate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Symbravo. No generic is listed as marketed.

20202025203020352040204501brand 2025data datePatent 10702535 listed to expire 11 April 2036Patent 10702602 listed to expire 11 April 2036Patent 11013806 listed to expire 11 April 2036Patent 10722583 listed to expire 11 April 2036Patent 10987358 listed to expire 11 April 2036Patent 10729696 listed to expire 11 April 2036Patent 10688102 listed to expire 11 April 2036Patent 11865117 listed to expire 11 April 2036Patent 10729697 listed to expire 11 April 2036Patent 11617755 listed to expire 11 April 2036Patent 10729773 listed to expire 11 April 2036Patent 10517950 listed to expire 11 April 2036Patent 11426414 listed to expire 11 April 2036Patent 9821075 listed to expire 11 April 2036Patent 10029010 listed to expire 11 April 2036Patent 10137131 listed to expire 11 April 2036Patent 10195278 listed to expire 11 April 2036Patent 10695429 listed to expire 11 April 2036Patent 10265324 listed to expire 11 April 2036Patent 11369684 listed to expire 11 April 2036Patent 10695430 listed to expire 11 April 2036Patent 10363312 listed to expire 11 April 2036Patent 10688185 listed to expire 11 April 2036Patent 10653777 listed to expire 11 April 2036Patent 10583144 listed to expire 11 April 2036Patent 11331323 listed to expire 11 April 2036Patent 10561664 listed to expire 11 April 2036Patent 10537642 listed to expire 11 April 2036Patent 10369224 listed to expire 11 April 2036Patent 10532101 listed to expire 11 April 2036Patent 11285213 listed to expire 11 April 2036Patent 10426839 listed to expire 11 April 2036Patent 10471014 listed to expire 11 April 2036Patent 11219626 listed to expire 11 April 2036Patent 10471069 listed to expire 11 April 2036Patent 10512692 listed to expire 11 April 2036Patent 11207328 listed to expire 11 April 2036Patent 10512693 listed to expire 11 April 2036Patent 11135295 listed to expire 11 April 2036Patent 11045549 listed to expire 11 April 2036Exclusivity NP to 30 January 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 30 January 2028Exclusivity NP Symbravo
  • 11 April 2036Patent 10702535
  • 11 April 2036Patent 10702602
  • 11 April 2036Patent 11013806
  • 11 April 2036Patent 10722583
  • 11 April 2036Patent 10987358
  • 11 April 2036Patent 10729696
  • 11 April 2036Patent 10688102
  • 11 April 2036Patent 11865117

88 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.